Last data update: Oct 28, 2024. (Total: 48004 publications since 2009)
Records 1-6 (of 6 Records) |
Query Trace: Pinner R[original query] |
---|
Baseline Asymptomatic Malaria Infection and Immunogenicity of rVSVG-ZEBOV-GP Vaccine: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE)
Mahon BE , Simon J , Widdowson MA , Samai M , Rogier E , Legardy-Williams J , Liu K , Schiffer J , Lange J , DeByle C , Pinner R , Schuchat A , Slutsker L , Goldstein S . J Infect Dis 2021 224 (11) 1907-1915 BACKGROUND: The effect of malaria infection on rVSVΔG-ZEBOV-GP (ERVEBO®) immunogenicity is unknown. METHODS: The Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) vaccinated 7998 asymptomatic adults with rVSVΔG-ZEBOV-GP during the 2014-6 Ebola epidemic. In STRIVE's immunogenicity sub-study, participants provided blood samples at baseline, 1, 6, and 9-12 months. Anti-glycoprotein (GP) binding and neutralizing antibodies were measured using validated assays. Baseline samples were tested for malaria parasites by PCR. RESULTS: Overall, 506 participants enrolled in the immunogenicity sub-study and had ≥1 post-vaccination antibody titer. Of 499 participants with a result, baseline malaria parasitemia was detected in 73(14.6%). All GP-ELISA and plaque reduction neutralization test (PRNT) geometric mean titers (GMTs) at 1, 6, and 9-12 months were above baseline, and 94.1% of participants seroresponded by GP-ELISA (≥2-fold rise AND ≥200 EU/ml), while 81.5% seroresponded by PRNT (≥4-fold rise) at ≥1 post-vaccination assessment. In participants with baseline malaria parasitemia, the PRNT seroresponse proportion was lower, while PRNT GMTs and GP-ELISA seroresponse and GMTs showed a trend toward lower responses at 6 and 9-12 months. CONCLUSION: Asymptomatic adults with and without malaria parasitemia had robust immune responses to rVSVΔG-ZEBOV-GP persisting for 9-12 months. Responses in those with malaria parasitemia were somewhat lower. |
Advances in public health surveillance and information dissemination at the Centers for Disease Control and Prevention
Richards CL , Iademarco MF , Atkinson D , Pinner RW , Yoon P , Mac Kenzie WR , Lee B , Qualters JR , Frieden TR . Public Health Rep 2017 132 (4) 33354917709542 Public health surveillance is the foundation of effective public health practice. Public health surveillance is defined as the ongoing systematic collection, analysis, and interpretation of data, closely integrated with the dissemination of these data to the public health practitioners, clinicians, and policy makers responsible for preventing and controlling disease and injury.1 Ideally, surveillance systems should support timely, efficient, flexible, scalable, and interoperable data acquisition, analysis, and dissemination. However, many current systems rely on disease-specific approaches that inhibit efficiency and interoperability (eg, manual data entry and data recoding that place a substantial burden on data partners) and use slow, inefficient, out-of-date technologies that no longer meet user needs for data management, analysis, visualization, and dissemination.2–4 Advances in information technology, data science, analytic methods, and information sharing provide an opportunity to substantially enhance surveillance. As a global leader in public health surveillance, the Centers for Disease Control and Prevention (CDC) is working with public health partners to transform and modernize CDC’s surveillance systems and approaches. Here, we describe recent enhancements in surveillance data analysis and visualization, information sharing, and dissemination at CDC and identify the challenges ahead. |
Implementing an Ebola vaccine study - Sierra Leone
Widdowson MA , Schrag SJ , Carter RJ , Carr W , Legardy-Williams J , Gibson L , Lisk DR , Jalloh MI , Bash-Taqi DA , Kargbo SA , Idriss A , Deen GF , Russell JB , McDonald W , Albert AP , Basket M , Callis A , Carter VM , Ogunsanya KR , Gee J , Pinner R , Mahon BE , Goldstein ST , Seward JF , Samai M , Schuchat A . MMWR Suppl 2016 65 (3) 98-106 In October 2014, the College of Medicine and Allied Health Sciences of the University of Sierra Leone, the Sierra Leone Ministry of Health and Sanitation, and CDC joined the global effort to accelerate assessment and availability of candidate Ebola vaccines and began planning for the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE). STRIVE was an individually randomized controlled phase II/III trial to evaluate efficacy, immunogenicity, and safety of the recombinant vesicular stomatitis virus Ebola vaccine (rVSV-ZEBOV). The study population was health care and frontline workers in select chiefdoms of the five most affected districts in Sierra Leone. Participants were randomized to receive a single intramuscular dose of rVSV-ZEBOV at enrollment or to receive a single intramuscular dose 18-24 weeks after enrollment. All participants were followed up monthly until 6 months after vaccination. Two substudies separately assessed detailed reactogenicity over 1 month and immunogenicity over 12 months. During the 5 months before the trial, STRIVE and partners built a research platform in Sierra Leone comprising participant follow-up sites, cold chain, reliable power supply, and vaccination clinics and hired and trained at least 350 national staff. Wide-ranging community outreach, informational sessions, and messaging were conducted before and during the trial to ensure full communication to the population of the study area regarding procedures and current knowledge about the trial vaccine. During April 9-August 15, 2015, STRIVE enrolled 8,673 participants, of whom 453 and 539 were also enrolled in the safety and immunogenicity substudies, respectively. As of April 28, 2016, no Ebola cases and no vaccine-related serious adverse events, which by regulatory definition include death, life-threatening illness, hospitalization or prolongation of hospitalization, or permanent disability, were reported in the study population. Although STRIVE will not produce an estimate of vaccine efficacy because of low case frequency as the epidemic was controlled, data on safety and immunogenicity will support decisions on licensure of rVSV-ZEBOV.The activities summarized in this report would not have been possible without collaboration with many U.S. and international partners (http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/partners.html). |
Effect of Culture-Independent Diagnostic Tests on Future Emerging Infections Program Surveillance.
Langley G , Besser J , Iwamoto M , Lessa FC , Cronquist A , Skoff TH , Chaves S , Boxrud D , Pinner RW , Harrison LH . Emerg Infect Dis 2015 21 (9) 1582-8 The Centers for Disease Control and Prevention Emerging Infections Program (EIP) network conducts population-based surveillance for pathogens of public health importance. Central to obtaining estimates of disease burden and tracking microbiological characteristics of these infections is accurate laboratory detection of pathogens. The use of culture-independent diagnostic tests (CIDTs) in clinical settings presents both opportunities and challenges to EIP surveillance. Because CIDTs offer better sensitivity than culture and are relatively easy to perform, their use could potentially improve estimates of disease burden. However, changes in clinical testing practices, use of tests with different sensitivities and specificities, and changes to case definitions make it challenging to monitor trends. Isolates are still needed for performing strain typing, antimicrobial resistance testing, and identifying other molecular characteristics of organisms. In this article, we outline current and future EIP activities to address issues associated with adoption of CIDTs, which may apply to other public health surveillance. |
Cultivation of an adaptive domestic network for surveillance and evaluation of emerging infections
Pinner RW , Lynfield R , Hadler JL , Schaffner W , Farley MM , Frank ME , Schuchat A . Emerg Infect Dis 2015 21 (9) 1499-509 Accomplishments of this program have provided numerous dividends and might benefit areas outside infectious diseases. |
Update on progress in electronic reporting of laboratory results to public health agencies - United States, 2014
Lamb E , Satre J , Hurd-Kundeti G , Liscek B , Hall CJ , Pinner RW , Conn L , Zajac J , Smallwood M , Smith K . MMWR Morb Mortal Wkly Rep 2015 64 (12) 328-30 Since 2010, CDC has provided resources from the Prevention and Public Health Fund of the Affordable Care Act to 57 state, local, and territorial health departments through the Epidemiology and Laboratory Capacity for Infectious Diseases cooperative agreement to assist with implementation of electronic laboratory reporting (ELR) from clinical and public health laboratories to public health agencies. To update information from a previous report about the progress in implementing ELR in the United States, CDC examined regular communications between the agency and the 57 health departments during 2012-2014. The results indicated that, as of July 2014, 67% of the approximately 20 million laboratory reports received annually for notifiable conditions were received electronically, compared with 62% in July 2013. These electronic reports were received by 55 of the 57 jurisdictions and came from 3,269 (up from nearly 2,900 in July 2013) of approximately 10,600 reporting laboratories. The proportion of laboratory reports received electronically varied by jurisdiction. In 2014, compared with 2013, the number of jurisdictions receiving >75% of laboratory reports electronically was higher (21 versus 14), and the number of jurisdictions receiving <25% of reports electronically was lower (seven versus nine). National implementation of ELR continues to increase and appears it might reach 80% of total laboratory report volume by 2016. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Oct 28, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure